Not to be outdone, Merck & Co countered with results from its LAG-3 favezelimab, with phase 1 data showing a combination with rival PD-1 Keytruda could have potential in metastatic colorectal cancer.

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 ...

this research resolves how the human LAG-3 receptor binds to HLA II molecules. First author Dr. Jan Petersen said, "The way ...